ライフサイエンスコーパス: Kaplan-Meier estimate

1 aluable study cohort of 20 patients was 61% (Kaplan-Meier estimate).

2 tation after blinatumomab treatment was 65% (Kaplan-Meier estimate).

3 ssessed by the incidence of RBC transfusion (Kaplan-Meier estimate).

4 tion-free survival at four months was 90.2% (Kaplan-Meier estimate).

5 in other countries (P<0.001, on the basis of Kaplan-Meier estimates).

6 progression for responders of 86.6 weeks by Kaplan-Meier estimate.

7 Survival rates were analyzed using Kaplan-Meier estimate.

8 Time to recurrence was calculated using Kaplan Meier estimates.

9 OS was compared by Kaplan-Meier estimates.

10 Incidence was estimated using Kaplan-Meier estimates.

11 lyzed according to recipient BMI class using Kaplan-Meier estimates.

12 were assessed by Cox regression analysis and Kaplan-Meier estimates.

13 Cumulative stroke risk was calculated using Kaplan-Meier estimates.

14 d graft survival, and patient survival using Kaplan-Meier estimates.

15 entia risk per sum score was calculated with Kaplan-Meier estimates.

16 Survival analysis was performed using Kaplan-Meier estimates.

17 Oncological outcome was assessed using Kaplan-Meier estimates.

18 ase activity-free intervals was evaluated by Kaplan-Meier estimates.

19 h time-to-event analysis ascertained through Kaplan-Meier estimates.

20 (PFS) and overall survival (OS) assessed by Kaplan-Meier estimates.

21 e to regression of seeds were estimated with Kaplan-Meier estimates.

22 absolute risks by calculating prevalence and Kaplan-Meier estimates.

23 g options had been lost in two participants (Kaplan-Meier estimate 0.7%) in the OT group and six (2.1

24 l (0.54; 95% CrI, 0.37-0.75) or the original Kaplan-Meier estimate (0.55; 95% CI, 0.40-0.74).

25 The Kaplan-Meier estimated 1-year rates of all-cause mortali

26 ent from those of patients treated with PTA (Kaplan-Meier estimates 1.8+/-0.7% versus 1.3+/-0.9%, 6.5

27 Kaplan-Meier-estimated 1-, 5-, 10-, and 15-year survival

28 basis of personalized cytogenetic profiles, Kaplan-Meier estimates (1, 3, and 5 years) for melanoma-

29 or renal failure (placebo, 75 events [60-day Kaplan-Meier estimate, 13.0%]; serelaxin, 76 events [13.

30 With median follow-up at 14.7 months, the Kaplan-Meier estimated 2-year survival rate was 79%.

31 stenting group (cumulative incidence, 24.6%; Kaplan-Meier estimate, 26.2%) and 45 patients in the end

32 Kaplan-Meier estimated 3-year survival rates from start

33 erectomy group (cumulative incidence, 26.9%; Kaplan-Meier estimate, 30.3%) (absolute difference in cu

34 ween TAVR and SAVR in the composite outcome (Kaplan-Meier estimates 38.0% vs. 36.3%, log-rank test p=

35 n randomisation and 120 days, there were 34 (Kaplan-Meier estimate 4.0%) events of disabling stroke o

36 Kaplan-Meier estimated 5-year disease-specific survival

37 Kaplan-Meier estimated 5-year overall survival and disea

38 Kaplan-Meier estimated 5-year rates of target vessel rev

39 d ICH during 5197 person-years of follow-up (Kaplan-Meier estimated 5-year risk 15.8%, 95% CI 13.7-17

40 reated with alemtuzumab (66 of 133 patients, Kaplan-Meier estimate 51.6%, 95% CI 43.2-60.7%) than pat

41 Based on Kaplan-Meier estimates, 59% of patients in the interfero

42 The Kaplan-Meier-estimated 6-month transition rates were 5.1

43 or stroke were similar in the three groups (Kaplan-Meier estimates, 6.5% in group 1, 5.6% in group 2

44 h alemtuzumab were free of CDA at 36 months (Kaplan-Meier estimate 71.8%, 95% CI 63.1-78.8%) compared

45 and 750 of 8881 in the placebo group (3-year Kaplan-Meier estimates 8.1%vs 9.7%, HR 0.80, 95% CI 0.72

46 Graft survival was high (Kaplan-Meier estimates: 92.7%, 92.5%, and 92.5%), as was

47 Kaplan-Meier estimates (95% CIs) for the incidence of th

48 es in all-cause mortality were examined with Kaplan-Meier estimates, adjusted logistic regression, an

49 rogression-free survival was evaluated using Kaplan-Meier estimates and a Cox proportional hazards re

50 We constructed Kaplan-Meier estimates and applied parametric survival a

51 Kaplan-Meier estimates and Cox models were used to evalu

52 erculosis-related deaths were assessed using Kaplan-Meier estimates and Cox models.

53 Kaplan-Meier estimates and Cox proportional hazard regre

54 We used Kaplan-Meier estimates and Cox proportional hazards mode

55 Using Kaplan-Meier estimates and Cox proportional hazards mode

56 We measured IUC discontinuation rates with Kaplan-Meier estimates and Cox proportional hazards mode

57 ata System database between 1988 and 1998 by Kaplan-Meier estimates and Cox proportional hazards mode

58 Kaplan-Meier estimates and Cox proportional hazards regr

59 We used Kaplan-Meier estimates and Cox regression to estimate an

60 inical and immunologic end points, by use of Kaplan-Meier estimates and Cox regression.

61 comes and graft survival were analyzed using Kaplan-Meier estimates and Cox univariate and multivaria

62 We compared overall survival using Kaplan-Meier estimates and equality of survival distribu

63 We used Kaplan-Meier estimates and log-rank tests to compare tim

64 Survival analyses were conducted using Kaplan-Meier estimates and multivariable Cox regression.

65 nary resuscitation organs was compared using Kaplan-Meier estimates and stratified log-rank test.

66 rates between the groups were compared with Kaplan-Meier estimates and the log-rank test.

67 Net failure was calculated using Kaplan-Meier estimates, and adjusted analyses employed f

68 and multivariate logistic regression models, Kaplan-Meier estimates, and Cox proportional hazards mod

69 noma-related mortality were calculated using Kaplan-Meier estimates, and Cox proportional hazards reg

70 Multivariable logistic regression, Kaplan-Meier estimates, and multivariable Cox regression

71 lyses were performed using log-rank test and Kaplan-Meier estimates, and multivariate analyses were p

72 ions among indicators and the log-rank test, Kaplan-Meier estimates, and multivariate Cox proportiona

73 OS was assessed with Kaplan-Meier estimates, and the Mantel-Cox log-rank test

74 Survival curves based on Kaplan-Meier estimates are presented.

75 ut no controls were diagnosed with CD (15.2% Kaplan-Meier estimate at 10 years).

76 Kaplan-Meier estimates at 1 and 5 years were used to com

77 Kaplan-Meier estimates at 2 years showed statistically s

78 Kaplan-Meier estimates at 7 years post-treatment reveale

79 Primary patency per Kaplan-Meier estimates at day 365 was 82.3% for DCB vers

80 istry and were 91.5% and 83.2% at 5 years by Kaplan-Meier estimates based on linked United Network fo

81 By Kaplan-Meier estimates, CG-positive patients showed earl

82 ssion-free survival (PFS) were explored with Kaplan-Meier estimates, Cox regression, and random survi

83 t, Kruskal-Wallis, Spearman correlation, and Kaplan-Meier estimates; Cox regression models were perfo

84 ients in the transvenous ICD group (48-month Kaplan-Meier estimated cumulative incidence, 15.1% and 1

85 At 3 years after coronary angiography, the Kaplan-Meier estimated cumulative percentages with event

86 f 5.8%(95%CI, -1.4%to 13.1%) [corrected].The Kaplan-Meier estimated cumulative percentages with event

87 The Kaplan-Meier estimated cumulative probability of virolog

88 Kaplan-Meier estimates demonstrated improved cumulative

89 Kaplan-Meier estimates demonstrated MACE rates at 1 year

90 d 42 patients in the control group (12-month Kaplan-Meier estimated event rate, 0.7% and 1.2%, respec

91 236 patients in the control group (12-month Kaplan-Meier estimated event rate, 6.0% and 6.9%, respec

92 cluding breast cancer, were calculated using Kaplan-Meier estimates, Fine and Gray competing-risks re

93 With a median follow-up of 39.7 months, the Kaplan-Meier estimate for 2-year overall survival was 98

94 Kaplan-Meier estimate for absence of metastatic disease

95 ls were collected every 6 months; the 4-year Kaplan-Meier estimate for incidence of HgbA1c levels >/=

96 Kaplan-Meier estimate for local control at 5 years was 7

97 The Kaplan-Meier estimate for local control was 85% at 3 yea

98 Kaplan-Meier estimate for melanoma-related metastasis in

99 The 24-month Kaplan-Meier estimate for orbital recurrence-free surviv

100 s with DCB were also superior to PTA per the Kaplan-Meier estimate for primary patency (89.0% versus

101 nts (age 67+/-16.2 years; 53.7% female), the Kaplan-Meier estimate for stroke/TIA recurrence within 1

102 The Kaplan-Meier estimate for the cumulative risk of extensi

103 The Kaplan-Meier estimates for 1-, 5-, and 10-year transplan

104 The Kaplan-Meier estimates for 1-year recipient survival wer

105 Kaplan-Meier estimates for both, patient-censored and de

106 Kaplan-Meier estimates for CABG and DES did not signific

107 9.6% when refCFVR </= 2.7 (P<0.001), whereas Kaplan-Meier estimates for cardiac mortality were 7.7% w

108 8-year Kaplan-Meier estimates for disease-free survival were 82

109 Endpoints included overall Kaplan-Meier estimates for hernia recurrence and postope

110 Overall, the 2-year Kaplan-Meier estimates for ocular survival, patient surv

111 8-year Kaplan-Meier estimates for overall survival were 91.8% (

112 iting times to transplant were obtained from Kaplan-Meier estimates for patients registered 1998-2000

113 The 10-year Kaplan-Meier estimates for RFS in arm A were 90.9% and 6

114 The Kaplan-Meier estimates for systemic metastasis in the me

115 Kaplan-Meier estimates for the PFS at 1, 5, and 10 years

116 Five- and 10-year metastasis-free Kaplan-Meier estimates for the recurrence-free group wer

117 Kaplan-Meier estimates for tumor recurrence in the 1995

118 Kaplan-Meier estimated freedom from PGTCS at end of the

119 At 12 months post-PPCI, the Kaplan-Meier-estimated frequencies of cardiac death or h

120 and 7.2%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio with saxagliptin, 1

121 , vs. 25% in the placebo group, according to Kaplan-Meier estimates; hazard ratio, 0.36; P=0.003).

122 and 12.4%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio, 1.02; 95% CI, 0.94

123 an-Meier estimate] vs 151/8849 [2.1%, 3-year Kaplan-Meier estimate], HR 1.61, 95% CI 1.31-1.97; p<0.0

124 ied end point and 21% (95% CI, 7% to 26%) by Kaplan-Meier estimate in a post hoc analysis using metho

125 < 3 years), and 20% (95% CI, 10% to 37%) by Kaplan-Meier estimate in post hoc analysis using definit

126 Kaplan-Meier estimates in the RCTs were compared with re

127 to 1.48; P=0.43); event rates were based on Kaplan-Meier estimates in time-to-event analyses.

128 Event rates were based on Kaplan-Meier estimates in time-to-first-event analyses.

129 The Kaplan-Meier estimated incidence of bleb-related infecti

130 By Kaplan-Meier estimates, iris nevus growth to melanoma oc

131 Clinical outcomes were analyzed with Kaplan-Meier estimates, log-rank comparisons, and Cox re

132 Kaplan-Meier estimated median duration of response was 1

133 with objective tumor regressions (31%), the Kaplan-Meier estimated median response duration was 2 ye

134 Kaplan-Meier estimated median time to progression (TTP)

135 In responders, Kaplan-Meier estimated median TTP was 12.6 months (range

136 of response (DR) have not been reached, but Kaplan-Meier estimated medians are 17.8 months (range, 5

137 The Kaplan-Meier estimated medians for duration of response,

138 By Kaplan-Meier estimates, metastasis in patients with ocul

139 Kaplan-Meier estimated mortality rates were 2.4% at 1 ye

140 Kaplan-Meier-estimated mortality was 3.2% at 30 days, 6.

141 Kaplan--Meier estimates of disease-free survival in pati

142 Kaplan--Meier estimates of disease-free survival stratif

143 The Kaplan-Meier estimate of 2-year survival was fit to the

144 .5 to 11.6 (median, 2.8) years, for a 3-year Kaplan-Meier estimate of 58% (CI, 43%-73%).

145 on revascularization when compared with PTA (Kaplan-Meier estimate of 74.5% versus 65.3%; log-rank P=

146 At 3 years, the overall Kaplan-Meier estimate of all-cause mortality was 32.7%.

147 atment was superior to short-term treatment (Kaplan-Meier estimate of difference 14.3% [5.1-23.6]; ha

148 .4% [95% CI 41.9-55.0] vs 56.4% [49.1-63.6]; Kaplan-Meier estimate of difference 7.9% [-1.9 to 17.7];

149 atients met the primary endpoint of relapse (Kaplan-Meier estimate of event rate 36.0% [95% CI 20.6-5

150 one of those assigned to continue treatment (Kaplan-Meier estimate of event rate 45.7% [95% CI 28.5-6

151 The 12-month Kaplan-Meier estimate of freedom from arrhythmia was 87.

152 The Kaplan-Meier estimate of freedom from cardiovascular hos

153 At 1 year, there were 139 deaths, and the Kaplan-Meier estimate of freedom from mortality was 76.8

154 The Kaplan-Meier estimate of local recurrence in the conserv

155 The 10-year Kaplan-Meier estimate of LRR was 4.% (95% CI, 2.3% to 6.

156 The Kaplan-Meier estimate of median survival was 12.5 months

157 The Kaplan-Meier estimate of median time to disease progress

158 The Kaplan-Meier estimate of median waiting time to transpla

159 Kaplan-Meier estimate of metastasis developing was 15% (

160 The Kaplan-Meier estimate of ocular survival at two years wa

161 The Kaplan-Meier estimate of overall survival (OS) for patie

162 The Kaplan-Meier estimate of overall survival at 3 years was

163 The Kaplan-Meier estimate of overall survival at 36 months w

164 The Kaplan-Meier estimate of overall survival was 38%.

165 The Kaplan-Meier estimate of patients free from corticostero

166 The overall Kaplan-Meier estimate of PCR-corrected efficacy of dihyd

167 an follow-up of 24 (range, 3-36) months, the Kaplan-Meier estimate of progression (>/= 1.0 point EDSS

168 The Kaplan-Meier estimate of proportion of patients undergoi

169 Kaplan-Meier estimate of relapse revealed patients with

170 The Kaplan-Meier estimate of the 1-year event rate of the co

171 The Kaplan-Meier estimate of the 36-month rate of overall su

172 The Kaplan-Meier estimate of the cumulative incidence of rej

173 The Kaplan-Meier estimate of the cumulative proportion of su

174 Kaplan-Meier estimate of the incidence of TIA /stroke wi

175 The Kaplan-Meier estimate of the median duration of hospital

176 The Kaplan-Meier estimate of the median duration of the resp

177 A Kaplan-Meier estimate of the median time to melanoma amo

178 point events occurred in the ablation group (Kaplan-Meier estimate of the percentage of patients with

179 The Kaplan-Meier estimate of the percentage of patients with

180 The Kaplan-Meier estimate of the percentage of patients with

181 The Kaplan-Meier estimate of the rate of the primary composi

182 The Kaplan-Meier estimate of the rate of the primary safety

183 The Kaplan-Meier estimate of the risk of relapse at the end

184 The Kaplan-Meier estimate of total risk of pregnancy loss wa

185 Kaplan-Meier estimates of 12-year all-cause mortality we

186 6-patient pooled nonrandomized DCB data set (Kaplan-Meier estimates of 2.1%, 4.9%, and 7.0% at 1, 2,

187 Kaplan-Meier estimates of 3-year PFS were 43% (95% CI 36

188 The Kaplan-Meier estimates of 3-year relapse-free survival (

189 Kaplan-Meier estimates of 5-year survival rates were 88%

190 Kaplan-Meier estimates of 6-month mortality declined fro

191 d placebo groups, respectively, resulting in Kaplan-Meier estimates of 77.2% (95% CI 71.87-82.51) of

192 Kaplan-Meier estimates of 8-year freedom from distant re

193 aspirin was associated with similar 180-day Kaplan-Meier estimates of adjudicated composite GI event

194 One-year Kaplan-Meier estimates of adverse event-free survival (d

195 Kaplan-Meier estimates of claims-defined versus trial-de

196 Kaplan-Meier estimates of composite efficacy failure-fre

197 Kaplan-Meier estimates of cumulative best rates of compl

198 Kaplan-Meier estimates of death at 1, 5, 10, and 20 year

199 Kaplan-Meier estimates of death at 5, 10, and 20 years w

200 At 30 months, the Kaplan-Meier estimates of DFS and OS from diagnosis were

201 At 4 years, the Kaplan-Meier estimates of DFS and OS from diagnosis were

202 The 18-month Kaplan-Meier estimates of disease-free survival were sig

203 int was demonstrated for Arm 2 versus Arm 1; Kaplan-Meier estimates of efficacy failure were 42.2% an

204 The Kaplan-Meier estimates of event-free survival at 8 years

205 Kaplan-Meier estimates of freedom from recurrent obstruc

206 Kaplan-Meier estimates of hard events were 0.5% versus 6

207 having 1.5% and 2.7% absolute reductions in Kaplan-Meier estimates of HHF risk at 4 years, respectiv

208 We produced Kaplan-Meier estimates of major adverse cardiovascular e

209 Kaplan-Meier estimates of median survival and descriptiv

210 Kaplan-Meier estimates of median time to progression in

211 After therapy, Kaplan-Meier estimates of metastasis at 1, 5, 10, and 20

212 After therapy, Kaplan-Meier estimates of metastasis at 5, 10, and 20 ye

213 The Kaplan-Meier estimates of mortality at day 60 did not di

214 Kaplan-Meier estimates of mortality for the whole study

215 310 deaths among patients without bleeding (Kaplan-Meier estimates of mortality, 4.5%, 10.0%, and 2.

216 In the development cohort, the Kaplan-Meier estimates of nursing home placement through

217 Two-year Kaplan-Meier estimates of ocular survival and disease-fr

218 The 36-month Kaplan-Meier estimates of ocular survival were 83.3% (95

219 Analyses of Kaplan-Meier estimates of OS by response and null Martin

220 Kaplan-Meier estimates of overall survival (OS) and even

221 Five-year Kaplan-Meier estimates of overall survival among patient

222 Kaplan-Meier estimates of overall survival at 3 years we

223 Four-year Kaplan-Meier estimates of patient survival in the Astagr

224 In the treatment group, Kaplan-Meier estimates of patient survival were 90.6% at

225 Kaplan-Meier estimates of patients alive and progression

226 After a median follow-up of 36 months, the Kaplan-Meier estimates of PFS were 86% (95% confidence i

227 Kaplan-Meier estimates of primary patency were 79% and 8

228 Week 24 Kaplan-Meier estimates of PTDM were similar for arm 1 ve

229 In both validation cohorts, the Kaplan-Meier estimates of recurrence confirmed that both

230 Kaplan-Meier estimates of recurrence for 1, 2, and 5 yea

231 ed the effect of selection for tracing using Kaplan-Meier estimates of reengagement among all patient

232 Kaplan-Meier estimates of seven-year survival for the to

233 s. 95%; p = 0.03 by log-rank test) on 5-year Kaplan-Meier estimates of survival after surgical AVR.

234 er or not there is evidence for such bias in Kaplan-Meier estimates of survival probabilities for car

235 Kaplan-Meier estimates of survival probability did not d

236 Kaplan-Meier estimates of survival were 82%, 76%, 68%, a

237 Visual acuity, Kaplan-Meier estimates of survival, local control, metas

238 gic data of 125 patients were compared using Kaplan-Meier estimates of survival.

239 Kaplan-Meier estimates of the actuarial incidence, which

240 Kaplan-Meier estimates of the cumulative incidence were

241 Kaplan-Meier estimates of the cumulative probabilities o

242 Kaplan-Meier estimates of the cumulative probability of

243 n group and in 584 in the placebo group; the Kaplan-Meier estimates of the incidence at 3 years were

244 mponent of the dual-design study, the 5-year Kaplan-Meier estimates of the incidence of arrhythmic ev

245 mponent of the dual-design study, the 5-year Kaplan-Meier estimates of the incidence of arrhythmic ev

246 103 (8.2 percent) in the control group; the Kaplan-Meier estimates of the likelihood of freedom from

247 Kaplan-Meier estimates of the OS rate at 1, 3, and 5 yea

248 Kaplan-Meier estimates of the primary endpoint across gr

249 Randomization to PPI therapy reduced 180-day Kaplan-Meier estimates of the primary GI endpoint in low

250 The Kaplan-Meier estimates of the rates of distant recurrenc

251 Kaplan-Meier estimates of the rates of the primary end p

252 Kaplan-Meier estimates of the recrudescence rate in the

253 Kaplan-Meier estimates of the stroke rate at days 2, 7,

254 two-tailed) for categorical comparisons, and Kaplan-Meier estimates of time to events of interest.

255 Kaplan-Meier estimates of time to regression and ocular

256 sation and adverse events were calculated as Kaplan-Meier estimates of time to the first event.

257 The Kaplan-Meier estimates of transplant-free survival from

258 A cumulative proportion of 85% (Kaplan-Meier estimate) of the 380 recovered subjects exp

259 The cumulative incidence (Kaplan-Meier estimate) of the primary end point was 5.5%

260 bjects experienced a recurrence, as did 58% (Kaplan-Meier estimate) of those who remained well for at

261 h test/validation set-defined cut points and Kaplan-Meier estimated outcome measures of 5-year overal

262 At 5 years, the Kaplan-Meier-estimated overall survival rates were 74% (

263 Kaplan Meier estimated patient and graft survivals for a

264 According to Kaplan-Meier estimates, patients with AT <40% of predict

265 The primary outcome was the Kaplan-Meier estimated percentage of patients who were f

266 se outcomes than patients with complete PVD (Kaplan-Meier estimated probability and standard error, 1

267 At 2 years, Kaplan-Meier-estimated progression-free survival was 73%

268 Kaplan-Meier estimated proportions of treatment failure

269 rsonalized cytogenetic profiles, with 5-year Kaplan-Meier estimates ranging from 4% with chromosomes

270 The Kaplan-Meier estimated recovery rate from dysthymic diso

271 Kaplan-Meier estimates results were similar in the per-p

272 Kaplan-Meier estimates showed a lower rate of death (12.

273 Kaplan-Meier estimates showed a reduction in the seconda

274 as not powered for survival as an end point, Kaplan-Meier estimates showed a trend in overall surviva

275 Kaplan-Meier estimates showed that 10-year adverse liver

276 Based on the Kaplan-Meier estimate, the probability of grade II-IV ac

277 Based on the results of Kaplan-Meier estimates, the time between baseline transt

278 ith secondary enucleation and metastases and Kaplan-Meier estimates to assess the probability of meta

279 Using Kaplan-Meier estimates to compare outcome, 30-day surviv

280 ther day of monitored hospitalization, using Kaplan-Meier estimates to determine the rate of resuscit

281 The Kaplan-Meier-estimated TTP was 6.8 months (range, 1.1 to

282 us the placebo group (241/8880 [3.4%, 3-year Kaplan-Meier estimate] vs 151/8849 [2.1%, 3-year Kaplan-

283 accumulation, and median overall survival by Kaplan-Meier estimate was not reached.

284 utero transmission of HIV-1 on the basis of Kaplan-Meier estimates was 5.7% (93 infants), with no si

285 Three-year rates by Kaplan-Meier estimate were 72% (95% CI, 56% to 84%) for

286 eiving placebo had elective surgical repair (Kaplan-Meier estimates were 16.1% for those receiving do

287 doresection groups, respectively, the 5-year Kaplan-Meier estimates were as follows: overall survival

288 Kaplan-Meier estimates were calculated for clinically si

289 Kaplan-Meier estimates were calculated for recurrences a

290 Kaplan-Meier estimates were plotted for disease-free sur

291 Kaplan-Meier estimates were used for OS analyses.

292 Kaplan-Meier estimates were used to assess graft surviva

293 iables, t test for continuous variables, and Kaplan-Meier estimates were used to describe events.

294 Kaplan-Meier estimates were used to investigate time to

295 mated "freedom of incisional hernia" curves (Kaplan-Meier estimate) were significantly different acro

296 A Kaplan-Meier estimate with a univariate model determined

297 We obtained Kaplan-Meier estimates with bootstrapped confidence inte

298 ll receiving tamoxifen alone; Cox models and Kaplan-Meier estimates with inverse probability of censo

299 th vorapaxar versus 28 of 8849 (0.4%, 3-year Kaplan-Meier estimate) with placebo (p=0.076).

300 ccurred in 43 of 8880 patients (0.6%, 3-year Kaplan-Meier estimate) with vorapaxar versus 28 of 8849